Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain

阅读量：

作者：

JM Vieitez，R García-Carbonero，J Aparicio，J Feliu，E González-Flores，E Grande，T Pérez-Hoyos，A Salud，E Torres，M Valero

展开

摘要：

Adjuvant chemotherapy is the current standard in the management of patients with localised colon cancer (CC) following curative resection. The use of oxaliplatin plus 5 fluorouracil/leucovorin ( FOLFOX ) or oxaliplatin plus capecitabine-based (XELOX) regimens, both approved in Europe as adjuvant treatment for stage III CC, has improved prognosis in this stage, but questions on their usefulness in high-risk stage II or elderly CC patients and on the role of some prognostic biomarkers are still pending. In April 2010, a consensus meeting on adjuvant CC treatment based on a revision of the most recent literature was held in Spain. The panel considered the use of adjuvant chemotherapy for high-risk stage II CC patients to be justified. Additionally, the more convenient administration of oral fluoropyrimidines vs. IV continuous infusion 5-FU would make XELOX a more suitable alternative for the patient. A more cautious decision should be taken when prescribing oxaliplatin treatment in patients aged ≥70.

展开

关键词：

Colorectal neoplasms Consensus Spain Antineoplastic agents Prognosis Tumour markers

DOI：

10.1007/s12094-011-0736-4

被引量：

年份：

2011